Literature DB >> 21660488

Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Yayu Tan1, Yadong Chen, Qidong You, Haopeng Sun, Manhua Li.   

Abstract

Blockade of the hERG K(+) channel has been identified as the most important mechanism of QT interval prolongation and thus inducing cardiac risk. In this work, an ensemble of 3D-QSAR pharmacophore models was constructed to provide insight into the determinants of the interactions between the hERG K(+) channel and channel inhibitors. To predict hERG inhibitory activities, the predicted values from the ensemble of models were averaged, and the results thus obtained showed that the predictive ability of the combined 3D-QSAR pharmacophore model was greater that those of the individual models. Also, using the same training and test sets, a 2D-QSAR model based on a heuristic machine-learning method was developed in order to analyze the physicochemical characters of hERG inhibitors. The models indicated that the inhibitors have certain key inhibitory features in common, including hydrophobicity, aromaticity, and flexibility. A final model was developed by combining the combined 3D-QSAR pharmacophore with the 2D-QSAR model, and this final model outperformed any other individual model, showing the highest predictive ability and the lowest deviation. This model can not only predict hERG inhibitory potency accurately, thus allowing fast cardiac safety evaluation, but it provides an effective tool for avoiding hERG inhibitory liability and thus enhanced cardiac risk in the design and optimization of new chemical entities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21660488     DOI: 10.1007/s00894-011-1136-y

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  95 in total

1.  A model for identifying HERG K+ channel blockers.

Authors:  Alex M Aronov; Brian B Goldman
Journal:  Bioorg Med Chem       Date:  2004-05-01       Impact factor: 3.641

2.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

3.  A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.

Authors:  Max K Leong
Journal:  Chem Res Toxicol       Date:  2007-01-30       Impact factor: 3.739

4.  Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.

Authors:  Toshihiko Myokai; Sunghi Ryu; Hirofumi Shimizu; Shigetoshi Oiki
Journal:  Mol Pharmacol       Date:  2008-03-07       Impact factor: 4.436

5.  Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents.

Authors:  Bengt R Danielsson; Kate Lansdell; Leslie Patmore; Torbjörn Tomson
Journal:  Epilepsy Res       Date:  2004-12-08       Impact factor: 3.045

6.  Exploring QSTR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques.

Authors:  Divita Garg; Tamanna Gandhi; C Gopi Mohan
Journal:  J Mol Graph Model       Date:  2007-08-17       Impact factor: 2.518

7.  Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Authors:  S Rajamani; L L Eckhardt; C R Valdivia; C A Klemens; B M Gillman; C L Anderson; K M Holzem; B P Delisle; B D Anson; J C Makielski; C T January
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

8.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

9.  Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656.

Authors:  Eberhard P Scholz; Franziska M Konrad; Daniel L Weiss; Edgar Zitron; Claudia Kiesecker; Ramona Bloehs; Martin Kulzer; Dierk Thomas; Sven Kathöfer; Alexander Bauer; Martin H Maurer; Gunnar Seemann; Hugo A Katus; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-27       Impact factor: 3.000

10.  Mechanism of the cardiotoxic actions of terfenadine.

Authors:  R L Woosley; Y Chen; J P Freiman; R A Gillis
Journal:  JAMA       Date:  1993 Mar 24-31       Impact factor: 56.272

View more
  8 in total

Review 1.  Computational methods of studying the binding of toxins from venomous animals to biological ion channels: theory and applications.

Authors:  Dan Gordon; Rong Chen; Shin-Ho Chung
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

2.  Novel Bayesian classification models for predicting compounds blocking hERG potassium channels.

Authors:  Li-li Liu; Jing Lu; Yin Lu; Ming-yue Zheng; Xiao-min Luo; Wei-liang Zhu; Hua-liang Jiang; Kai-xian Chen
Journal:  Acta Pharmacol Sin       Date:  2014-06-30       Impact factor: 6.150

3.  Pharmacological, Physiochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogues Used in Metabolic Glycoengineering.

Authors:  Christopher T Saeui; Lingshu Liu; Esteban Urias; Justin Morrissette-McAlmon; Rahul Bhattacharya; Kevin J Yarema
Journal:  Mol Pharm       Date:  2017-09-13       Impact factor: 4.939

4.  Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study.

Authors:  Teresa Maria Creanza; Pietro Delre; Nicola Ancona; Giovanni Lentini; Michele Saviano; Giuseppe Felice Mangiatordi
Journal:  J Chem Inf Model       Date:  2021-09-10       Impact factor: 6.162

5.  Tuning HERG out: antitarget QSAR models for drug development.

Authors:  Rodolpho C Braga; Vinicius M Alves; Meryck F B Silva; Eugene Muratov; Denis Fourches; Alexander Tropsha; Carolina H Andrade
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 6.  Natural products modulating the hERG channel: heartaches and hope.

Authors:  Jadel M Kratz; Ulrike Grienke; Olaf Scheel; Stefan A Mann; Judith M Rollinger
Journal:  Nat Prod Rep       Date:  2017-08-02       Impact factor: 13.423

7.  Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities.

Authors:  Saba Munawar; Monique J Windley; Edwin G Tse; Matthew H Todd; Adam P Hill; Jamie I Vandenberg; Ishrat Jabeen
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

8.  Capsule Networks Showed Excellent Performance in the Classification of hERG Blockers/Nonblockers.

Authors:  Yiwei Wang; Lei Huang; Siwen Jiang; Yifei Wang; Jun Zou; Hongguang Fu; Shengyong Yang
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.